A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
- Conditions
- Neoplasms
- Registration Number
- NCT00390676
- Lead Sponsor
- Adherex Technologies, Inc.
- Brief Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
Rocky Mountain Cancer Centers
🇺🇸Denver, Colorado, United States
Cancer Centers of Florida
🇺🇸Ocoee, Florida, United States
Central Indiana Cancer Centers
🇺🇸Indianapolis, Indiana, United States
New York Oncology Hematology P.C.
🇺🇸Albany, New York, United States
Dayton Oncology & Hematology, P.A
🇺🇸Kettering, Ohio, United States
Cancer Centers of the Carolinas
🇺🇸Greenville, South Carolina, United States
Texas Oncology, PA
🇺🇸Dallas, Texas, United States
Tyler Cancer Center
🇺🇸Tyler, Texas, United States
Virginia Oncology Associates
🇺🇸Norfolk, Virginia, United States
Northwest Cancer Specialists - Vancouver Cancer Center
🇺🇸Vancouver, Washington, United States
Rocky Mountain Cancer Centers🇺🇸Denver, Colorado, United States